<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="48716">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02472015</url>
  </required_header>
  <id_info>
    <org_study_id>13 7031 08</org_study_id>
    <nct_id>NCT02472015</nct_id>
  </id_info>
  <brief_title>Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms</brief_title>
  <acronym>DETECT</acronym>
  <official_title>Dementia in Long Term Care Facilities: Telemedicine for the Management of Neuropsychiatric Symptoms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Toulouse</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Toulouse</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Telemedicine may facilitate adequate treatment of Neuropsychiatric symptoms (NPS) by
      identifying underlying causes and tailoring a treatment plan (pharmacological or
      non-pharmacologic treatments including provision of staff education and support, training in
      problem solving, and targeted therapy directed at the underlying causes for specific
      behaviors).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During a 6-months period, patients will be included in both arms, whenever they present a
      disruptive NPS that requires a specialist consultation based on the long-term care facility
      (LTCF) staff judgment. In the intervention group, a telemedicine (TM) consultation between
      the LTCF staff (medical and nurse staff) and the Memory Center from the University Hospital,
      will occur at inclusion (T0). Then, a second TM consultation will occur at 1 month (T1). In
      the control group management of NPS will be done as usual care. In both groups, patients'
      parameters such as non-programmed hospitalizations and/or consultations due to disruptive
      NPS, psychotropic drugs use, and health costs, will be evaluated at inclusion, 1 month and
      at 2 months. Acceptability of the TM among the LTCF staff will be assessed during the study
      in the intervention group.

      In this study, patients will be included by the University Hospital of Toulouse and the
      University Hospital of Limoges.

      These two university hospitals are composed of a group of institutions for elderly people
      located near Toulouse and Limoges.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">November 2016</completion_date>
  <primary_completion_date type="Anticipated">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acceptability of the TM among the LTCF staff</measure>
    <time_frame>6 months</time_frame>
    <description>Acceptability of the telemedicine (TM) among the LTCF staff which will be assessed in the intervention group by quantitative indicators (proportion of the solicitation of the TM solution among patients with disruptive NPS, the delay to obtain a TM consultation and the number of the staff participants at each TM consultation) and qualitative indicators (staff global satisfaction will be evaluated by focus groups and interviewing).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of non-programmed hospitalizations and/or consultation due to disruptive NPS</measure>
    <time_frame>6 months</time_frame>
    <description>Calculation of the rate of non-programmed hospitalizations and/or consultation due to disruptive NPS in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The psychotropic drugs used</measure>
    <time_frame>6 months</time_frame>
    <description>Description of psychotropic drugs used in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe the health costs</measure>
    <time_frame>6 months</time_frame>
    <description>Description of the health costs in both groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>describe the estimation of the cluster effect (&quot;design effect&quot;)</measure>
    <time_frame>6 months</time_frame>
    <description>Estimation of the cluster effect (&quot;design effect&quot;) in both groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>normal care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>patients who will have normal care</description>
  </arm_group>
  <arm_group>
    <arm_group_label>telemedicine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who will have telemedicine</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>telemedicine</intervention_name>
    <description>psycho-behavioural care by telemedicine</description>
    <arm_group_label>telemedicine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patient aged 65 or more, with a dementia diagnosed by a specialist or the general
             practitioner;

          -  patient presenting with a disruptive NPS as defined in HAS recommendations (2009),
             that requires a specialist consultation based on the LTCF staff judgment;

          -  informed and written consent by the patient or the legal representative or the
             reliable person when appropriate;

          -  general practitioner agreement.

        Exclusion Criteria:

          -  patient's life expectancy less than 6 months;

          -  Non agreement of study participation of patients or legal representative or the
             reliable person when appropriate.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Soto, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Toulouse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maria Soto, MD</last_name>
    <phone>05 61 14 56 68</phone>
    <phone_ext>+33</phone_ext>
    <email>soto-martin.me@chu-toulouse.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>UHLimoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierry DANTOINE, MD</last_name>
      <phone>05 55 05 86 26</phone>
      <phone_ext>+33</phone_ext>
      <email>thierry.dantoine@chu-limoges.fr</email>
    </contact>
    <investigator>
      <last_name>Martine PELAUDEIX, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Stéphan MAYER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Patrice MIGLIORINI, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sandrine VAN HEUNEN, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Noelle CHARLES, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Marie-Françoise ALBERNY, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Thierry DANTOINE, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UHToulouse</name>
      <address>
        <city>Toulouse</city>
        <zip>31300</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Soto, MD</last_name>
      <phone>05 61 14 56 68</phone>
      <phone_ext>+33</phone_ext>
      <email>soto-martin.me@chu-toulouse.fr</email>
    </contact>
    <investigator>
      <last_name>Antoine Piau, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Fati Nourhashémi, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yves Rolland, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Bruno Vellas, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christophe Hein, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre Rumeau, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ingrid Binot, Doctor</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>August 2015</verification_date>
  <lastchanged_date>August 18, 2015</lastchanged_date>
  <firstreceived_date>June 1, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>neuropsychiatric symptoms</keyword>
  <keyword>dementia</keyword>
  <keyword>telemedicine</keyword>
  <keyword>long-term care facilities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
